FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年8月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Viewpoint - Guichuang Tongqiao reported strong financial performance for the first half of 2025, with significant growth in both revenue and net profit, driven by the expansion of its neurovascular and peripheral vascular intervention businesses [1][2]. Financial Performance - The company achieved operating revenue of 482 million yuan, a year-on-year increase of 31.7% [1]. - Net profit reached 121 million yuan, reflecting a year-on-year growth of 76.0% [1]. - The neurovascular intervention business generated approximately 304 million yuan in revenue, up 25.0% year-on-year, while the peripheral vascular intervention business saw revenue of about 176 million yuan, a 46.2% increase [1]. Operational Efficiency - The company improved operational efficiency, with research and development, sales, and management expense ratios decreasing by 7 percentage points compared to the same period last year [1]. - The company has established a wide distribution network covering over 3,000 hospitals [2]. International Business Growth - Guichuang Tongqiao's overseas business showed rapid growth, achieving operating revenue of 15.72 million yuan [1]. - The company has 22 products commercialized in 27 countries and regions, with over 31 products in the registration process across 23 countries [1]. - The overseas revenue proportion is steadily increasing, becoming a new growth driver for the company [1]. Product Development and Innovation - The company has a product pipeline of 73 items, with 50 approved by the National Medical Products Administration (NMPA) [2]. - New products launched this year include the ZYLOX Eagle thrombectomy system and the Tongqiao Shunfeng balloon hemostatic device, enhancing the product matrix [2]. - The company focuses on differentiated innovation to meet unmet clinical needs, aiming to provide comprehensive solutions for patients [2][3]. Future Outlook - Guichuang Tongqiao aims to expand market share through procurement and enhance international business layout to improve global market coverage [3]. - The company is committed to developing differentiated innovative products with real clinical value to ensure long-term stable growth [3].

Core Insights - The company achieved a revenue of RMB 482 million in the first half of 2025, representing a year-on-year growth of 31.7%, primarily driven by sales growth in the neurovascular and peripheral vascular intervention device segments [1] - Net profit increased by 76% to RMB 121.2 million, while adjusted net profit grew by 68.1% to RMB 131.4 million [1] - Research and development expenses rose by 19.7% to RMB 121.6 million, aimed at new product launches and innovation in the product pipeline [1] Revenue and Profitability - International business revenue saw a significant increase of 36.9%, with products now covering seven of the top ten global markets [1] - The company has established strategic partnerships with over 60 local partners, expanding its channel coverage to 52 countries and regions worldwide [1] Market Presence and Strategy - The company is actively conducting post-market clinical follow-up trials for CE-marked products in Europe to enhance quality recognition and brand awareness [1] - Support has been garnered from well-known hospital groups such as Asklepios and SANA, indicating strong market positioning and credibility [1]

Major Events - CSPC Pharmaceutical Group (01093) received clinical trial approval for Dupilumab injection in China [1] - Rongchang Biopharmaceutical (09995) was granted breakthrough therapy designation for RC148 for non-small cell lung cancer by the National Medical Products Administration [1] - China Biologic Products (01177) included LM-302 "CLDN18.2 ADC" in the breakthrough therapy program [1] - Sunshine Oilsands (02012) plans to acquire 51% stake in Noble Technology Limited for HKD 50.91945 million [1] - Galenica Pharmaceutical-B (01672) plans to issue shares at a discount of approximately 9.9%, raising HKD 468 million [1] Financial Performance - Xiaomi Group-W (01810) reported record high revenue and profit for Q2, with attributable profit of HKD 11.904 billion, up 133.51% year-on-year [1] - Pop Mart (09992) announced a mid-term profit of HKD 4.574 billion, a year-on-year increase of 396.5% [1] - Fuyao Glass (03606) reported a half-year net profit of approximately HKD 4.805 billion, up 37.33% year-on-year [1] - China Resources Beer (00291) announced a mid-term profit of HKD 5.789 billion, an increase of 23.04% year-on-year [1] - Kunlun Energy (00135) reported a mid-term profit of HKD 3.161 billion, down 4.36% year-on-year, with a dividend of HKD 0.166 per share [1] - WuXi Biologics (02269) reported a mid-term profit of approximately HKD 2.339 billion, up 56% year-on-year [1] - Sunny Optical Technology (02382) announced a mid-term profit of HKD 1.646 billion, an increase of 52.56% year-on-year [1] - Yixin Group (02858) reported an adjusted net profit of HKD 648 million, up 28% year-on-year [1] - Kangchen Pharmaceutical (01681) reported a mid-term profit of HKD 498 million, up 24.6% year-on-year, maintaining market leadership with its flagship product [1] - Ping An Good Doctor (01833) reported a mid-term profit of HKD 134 million, a year-on-year increase of 136.84% [1] - China Communication Services (02342) reported a mid-term profit of HKD 61.781 million, returning to profitability [1] - XPeng Motors-W (09868) achieved record levels in core business and financial metrics for Q2, with a net loss of HKD 480 million, narrowing by 62.8% year-on-year [1] - Guochuang Tongqiao (02190) reported a mid-term profit of HKD 121 million, up 76% year-on-year [1] - Yanda Pharmaceutical (00512) reported record revenue of HKD 6.107 billion [1] - Jinli Permanent Magnet (06680) reported a mid-term profit of approximately HKD 305 million, up 154.81% year-on-year [1] - Zhaogang Group-W (06676) issued a profit warning, expecting a mid-term profit of approximately HKD 140 million to HKD 180 million, returning to profitability [1] - Longyuan Power (00916) reported a mid-term profit of HKD 3.519 billion, down 14.4% year-on-year [1] - Yancoal Australia (03668) reported a mid-term profit of AUD 16.3 million, down 61.19% year-on-year [1] - SF Holding (06936) reported total revenue of HKD 24.847 billion for July in logistics, supply chain, and international business, up 9.95% year-on-year [1] - Chow Sang Sang (00116) expects a mid-term profit from continuing operations of approximately HKD 900 million to HKD 920 million [1]

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. reported strong financial performance for the first half of 2025, with significant growth in both revenue and net profit [1] Financial Performance - The company achieved a revenue of 482 million yuan, representing a year-on-year increase of 31.7% [1] - Net profit exceeded 121 million yuan, showing a year-on-year growth of 76% [1] Business Segments - The neurovascular intervention segment generated approximately 304 million yuan in revenue, reflecting a year-on-year growth of 25% [1] - The peripheral vascular intervention segment reported revenue of about 176 million yuan, with a year-on-year increase of 46.2% [1] International Operations - Overseas business generated revenue of 15.72 million yuan, with 22 products commercialized in 27 countries and regions [1] - The company is advancing the registration of over 31 products in 23 countries and regions, with global coverage in 52 countries and regions [1] - Collaborations have been established with more than 60 local partners [1]

Core Viewpoint - The company, Zhichuang Tongqiao (02190), announced the approval of a proposed share incentive plan by its board of directors, which is set to be reviewed on August 19, 2025, and requires shareholder approval to be implemented [1] Group 1 - The share incentive plan will involve the issuance of new H-shares, including the transfer of treasury shares, thus constituting a share plan as defined under Chapter 17 of the Listing Rules [1] - The implementation of the share incentive plan is contingent upon receiving approval from the shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Zylox-Tonbridge Medical Technology Co., Ltd. 於2025年8月19日，董事會審議及批准有關建議採納股份激勵計劃的決議案。 股份激勵計劃將以發行新H股（包括轉讓庫存股）撥資，因而構成《上市規則》第 十七章所界定涉及本公司發行新股份的股份計劃。採納股份激勵計劃須待股 東批准後，方可作實。 股份激勵計劃的主要條款概述如下： 1. 目的 歸創通橋醫療科技股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2190） 建議採納股份激勵計劃 及 建議授權董事會及╱或管理委員會 辦理股份激勵計劃相關事宜 建議採納股份激勵計劃 股份激勵計劃的目的為(i)確保實現本公司的長期經營目標及發展策略；(ii) 建立及完善對本公司高級管理層、中級管理層及其他骨幹員工的激勵和 約束機制、穩定和吸引優秀的各類人才，藉以提升本公司的市 ...

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. reported significant growth in revenue and net profit for the first half of 2025, driven by strong performance in neurovascular and peripheral vascular intervention businesses [1] Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 482 million yuan, a year-on-year increase of 31.7% [1] - Net profit exceeded 121 million yuan, representing a substantial growth of 76.0%, with a net profit margin of 25.1% [1] - The company improved operational efficiency, with R&D, sales, and management expense ratios decreasing by 7 percentage points compared to the same period last year [1] Group 2: Business Segments - Neurovascular intervention business generated approximately 304 million yuan in revenue, up 25.0% year-on-year [1] - Peripheral vascular intervention business achieved revenue of about 176 million yuan, marking a 46.2% increase [1] - The company has established a wide distribution network covering over 3,000 hospitals, with over 1 million clinical uses of its products since commercialization [2] Group 3: Product Development and Innovation - The company launched several innovative products, including the ZYLOX Eagle thrombectomy system and the Tongqiao Shun sealing balloon hemostatic device, enhancing its product portfolio [3] - As of the announcement date, the company has established a pipeline of 73 products, with 50 products approved by NMPA [3] - The ZYLOX Mammoth large-bore thrombectomy catheter is the only 12F-18F large-bore catheter in China, offering innovative treatment solutions for deep vein thrombosis patients [3] Group 4: International Expansion - The company is expanding its international business, with products covering seven of the top ten global markets, including France, Germany, and Italy [4] - In emerging markets, the ZYLOX Unicorn vascular suturing system was approved in Indonesia, marking the company's first product launch in Southeast Asia [4] - The company is actively participating in international academic conferences to enhance brand recognition and has gained support from renowned overseas hospital groups [4]

Core Insights - Guichuang Tongqiao Medical Technology Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, with revenue reaching 482 million yuan, a year-on-year growth of 31.7%, and net profit exceeding 121 million yuan, a substantial increase of 76.0% [1] - The company continues to drive steady growth in its neurovascular and peripheral vascular intervention businesses, with neurovascular intervention revenue at approximately 304 million yuan (up 25.0%) and peripheral vascular intervention revenue at approximately 176 million yuan (up 46.2%) [1] - The company is expanding its international business rapidly, with overseas revenue reaching 15.72 million yuan, and has established a commercial presence in 27 countries and regions with 22 products [1] Group 1: Financial Performance - In the first half of 2025, the company achieved a net profit margin of 25.1% [1] - The company improved operational efficiency, with R&D, sales, and management expense ratios decreasing by 7 percentage points compared to the same period last year [1] Group 2: Product Development and Market Expansion - The company has a robust product pipeline with 73 products, of which 50 have received NMPA approval [3] - New products launched this year include the ZYLOX Eagle® thrombectomy system and the Tongqiao Shunfeng™ balloon occlusion hemostatic device, enhancing the product matrix [3] - The company has established a wide distribution network covering over 3,000 hospitals, with clinical usage exceeding 1 million since commercialization [2] Group 3: International Business Growth - The company is actively expanding its international market presence, having products in seven of the top ten global markets, including France, Germany, and Italy [4] - In emerging markets, the ZYLOX Unicorn™ vascular suturing system has been approved in Indonesia, marking the company's first product launch in Southeast Asia [4] - The company aims to enhance its global market coverage and focus on differentiated innovative products to support long-term sustainable development [4]

上半年，公司依托丰富且高品质的产品组合，在专业及高效的商业化团队推动下，延续多轮集采中标的 良好态势，实现销售规模快速增长。同时，受益于集采政策逐渐温和，公司多款集采中选产品顺利续 标，有望在新周期继续推动产品上量及市场份额提升。 报告期内，公司通桥银蛇?颅内中间导管系列、神经血管导丝、通桥麒麟?血流导向密网支架、 UltraFree?药物洗脱PTA球囊扩张导管、ZYLOX Octoplus?腔静脉滤器等产品销售规模大幅增长，市场渗 透率稳步提升。在江苏省医用耗材集采接续采购中，通桥凤?颅内动脉瘤栓塞弹簧圈顺利完成续标。截 至目前，公司已建立广泛的分销网络，覆盖超过3000家医院。公司产品自商业化以来，在临床场景的使 用数量已经突破100万个，持续为全球患者带去高质量且可负担的产品和解决方案。 在持续推进成熟产品商业化落地的同时，公司坚持差异化创新以更好满足未被满足的临床需求。今年以 来，ZYLOX Eagle?血栓抽吸系统、通桥舜封?球囊封堵止血器等产品陆续获批上市，进一步丰富产品矩 阵。下半年，大腔外周血栓抽吸导管、辅助栓塞支架、OCT引导外周血管斑块定向旋切导引导管系列均 有望获批上市。ZYLOX Ma ...